















conflClinical trial outcomes and thoracic aortic morphometry after one
year with the Valiant Navion stent graft system
Fabio Verzini, MD, PhD, FEBVS,a Nimesh Desai, MD, PhD,b Frank R. Arko III, MD,c Jean M. Panneton, MD,d
Fabien Thaveau, MD, PhD,e Francois Dagenais, MD,f Jia Guo, PhD,g and Ali Azizzadeh, MD, FACS,h Turin, Italy;
Philadelphia, Pa; Charlotte, NC; Norfolk, Va; Strasbourg, France; Quebec City, Quebec, Canada; and Santa Rosa and Los
Angeles, CalifABSTRACT
Authors’ Note: On February 17, 2021, Medtronic Incorporated issued a global voluntary recall of the Valiant Navion
Thoracic Stent Graft System (the device under study in the Valiant Evo Global Clinical Program that is the subject of this
publication), and instructed physicians to immediately cease use of the Valiant Navion system and return any unused
product. Medtronic initiated the recall in response to three clinical trial subjects recently observed with stent fractures,
two of whom have confirmed type IIIb endoleaks. The data collection, analysis, and manuscript submission occurred
before the notice of this recall, and, specifically, the 100 procedures reviewed for this series were free of events at 1 year
related to the reason for this device recall. The authors of this article and the manufacturer were unaware of the recently
detected adverse events at the time of the preparation of the manuscript, and the 1-year trial results, and imaging-based
analyses described are unchanged.
Management of thoracic aortic aneurysms continues to be a challenging problem and outcomes are dependent on
patient anatomy. The present publication focuses on the importance of achieving proximal and distal seals and the
consideration of the temporal changes of the aortic morphology as a part of the TEVAR planning process. The authors
believe there is still scientific merit in disclosing this information, despite the current nonavailability of the Valiant Navion
system.
Objective: The Valiant Navion stent graft system (Medtronic Inc, Santa Rosa, Calif) is a third-generation device with
improved conformability. We have reported the 1-year clinical trial outcomes, with a focus on an imaging-based analysis
of the aortic morphology. We assessed the effects of graft implantation on the native anatomy and the effects of the 1-
year changes in thoracic aorta morphology on the original seal zones of the stent graft.
Methods: A total of 100 subjects were enrolled in a prospective single-arm clinical trial investigating the Valiant Navion
stent graft system. An independent core laboratory (Syntactx, New York, NY) assessed the anatomic characteristics and
performance outcomes.
Results: Through 1 year of follow-up, the freedom from all-cause mortality, aneurysm-related mortality, and secondary
procedures was 89.8%, 97.0%, and 94.8% respectively. Of the 100 patients, 5 had undergone a total of six secondary
procedures, and 9 patients had developed an endoleak (type Ia and Ib in 1, type Ia in 1, type Ib in 3, and type II in 4
patients) within the first year. After 1 year, 2 of 76 patients (2.6%) had had an increase in their maximum aneurysm
diameter of $5 mm, 62 (81.6%) had had stable sacs, and 12 (15.8%) had experienced sac shrinkage. Although no
deployment failures had occurred, 36 of the 100 proximal (36%) and 31 of the 100 distal (31%) attachment zones were
considered short according to our definitions. The stent graft had conformed to the native anatomy at implantation,
because the preprocedural thoracic aorta tortuosity (1.45 6 0.02) had not significantly changed at 1 month after im-
plantation (1.466 0.02). Despite a natural increase in thoracic tortuosity after 1 year (1.496 0.02), wall apposition had been
maintained over time, as evidenced by the low endoleak rates. Aortic elongation and dilation had occurred at thee Unit of Vascular Surgery, Department of Surgical Sciences, University
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August 2021proximal end of the graft by an average of 1.2 mm and 1.6 mm, respectively. Aortic remodeling was more pronounced at
the distal end, with an average increase of 4.2 mm in length and 2.8 mm in diameter.
Conclusions: The included patients had had positive 1-year outcomes with high freedom from mortality, endoleak
development, and secondary procedures. Aortic elongation and dilation were more prevalent at the distal end,
emphasizing the importance of distal attachment zone consideration as part of preoperative planning. Because aortic
remodeling can be expected to continue over time, additional follow-up and imaging analysis in the trial will be
necessary to assess the aortic morphology and its effects on stent graft performance. (J Vasc Surg 2021;74:569-78.)
Keywords: Aortic aneurysm; TEVAR; Thoracic aorta; Thoracic endovascular aortic repair; Thoracic stent graftPatient anatomy can affect the seal created by a stent
graft,1,2 and this is critically important in determining
the outcomes after thoracic endovascular aneurysm
repair (TEVAR). Anatomic features such as wide necks,
short necks, and excessive tortuosity of the aorta have
been associated with type IA endoleaks, migration, and
other complications.2-4 At the distal end, inaccurate posi-
tioning of the graft has been reported to be associated
with migration and the occurrence of type Ib endoleaks.5
Excessive oversizing can also lead to an increased risk of
aortic wall lesions, both proximally and distally.6
Changes to the native anatomy immediately after stent
graft implantation and aortic remodeling over time are
additional anatomic factors that deserve further investi-
gation. Stent graft-induced retrograde dissection is a
commonly discussed effect that the graft might have
on the native anatomy.7,8 The placement of a TEVAR de-
vice can change the curvature of the aorta,9,10 which
could be a concern for patients with a fragile aorta.
Also, a natural increase in the diameter, length, and cur-
vature of the thoracic aorta occurs over time,11,12 and this
remodeling should be considered when planning the
initial procedure.
The Valiant Navion stent graft system (Medtronic Inc,
Santa Rosa, Calif) is a third-generation device with
improved conformability and positive outcomes re-
ported in a 30-day primary end point study.13 In the pre-
sent report, we have described the 1-year clinical trial
outcomes with an imaging analysis examining the ef-
fects of graft implantation on the native anatomy and
the effects of 1-year aortic remodeling on stent graft
performance.
METHODS
Trial method. The complete details on the Valiant Evo
International Clinical Trial (ClinicalTrials.gov identifier,
NCT02625324) and VEVO (Valient Evo US Clinical Trial;
ClinicalTrials.gov identifier, NCT02652949) have been pre-
viously reported.13 In brief, the trials were prospective,
nonrandomized, single-arm investigations of the perfor-
mance of the Valiant Navion stent graft system (Med-
tronic) for the treatment of descending thoracic aortic
aneurysms and penetrating atherosclerotic ulcers
(PAUs). One detail of the Navion stent graft design rele-
vant to the present study is that the proximal end of thestent graft is available with a bare stent (FreeFlo) and
without a bare stent (CoveredSeal). A total of 100 pa-
tients were enrolled from 2016 to 2018, with 53 from 18
U.S. sites and 47 from 15 sites outside of the United
States. The institutional review board or ethics commit-
tee of each site approved the clinical trials, as applicable,
which were performed in accordance with the clinical
investigation protocol, and all the patients had provided
written informed consent. The trials were conducted in
compliance with the Declaration of Helsinki (October
2013) and the laws and regulations of the countries in
which the clinical trials were conducted.
Clinical trial and imaging data. The definitions of the
primary composite end point and other outcomes have
been reported in detail in the 30-day study.13 An inde-
pendent core laboratory (Syntactx, New York, NY) was
responsible for the assessment of the anatomic charac-
teristics and stent graft measurements. For the imaging-
based analyses, all diameter measurements were per-
formed from the intima to the intima, with the exception
of the maximum thoracic aortic diameter, which was
measured from the adventitia to the adventitia, and the
iliac minimum diameters, which were luminal. The
maximum aneurysm diameter changes at 1 year were
assessed using the 1-month imaging findings as the
baseline, and the definitions for sac increases, stability,
and decreases followed the reported standards for sac
dynamics.14 The aortic measurements were defined as
follows (Fig 1):
d Tortuosity: centerline length divided by the straight line
length from the proximal to distal end of the arterial
segment (the thoracic aorta was defined as the left
common carotid artery to the celiac artery and the
abdominal aorta as the celiac artery to aortic
bifurcation)
d Proximal oversizing: proximal diameter of the proximal
stent graft divided by the aortic diameter immediately
proximal to the aneurysm, minus one
d Proximal neck length: centerline distance from the
proximal edge of the site-specified landing zone to
the proximal edge of the aneurysm (aortic diameter
increased by 10%) determined from the preprocedural
imaging study
d Proximal attachment zone (PAZ) length: centerline
distance within the proximal seal zone from the
ARTICLE HIGHLIGHTS
d Type of Research: A multicenter, prospective, non-
randomized trial
d Key Findings: A total of 100 subjects with a descend-
ing thoracic aneurysm or penetrating atherosclerotic
ulcer were treated with the Valiant Navion stent graft
(Medtronic Inc, Santa Rosa, Calif). The 1-year freedom
from all-cause mortality and secondary procedures
was 89.8% and 94.8%, respectively. The graft con-
formed to the native thoracic aorta tortuosity at
implant and through 1 year of follow-up. Aortic elon-
gation and dilation had occurred more often at the
distal end of the stent graft.
d Take Home Message: The 1-year results with the
Navion stent graft were positive, and the imaging
analysis showed the importance of the seal zone
length and oversizing to address the natural changes
in aortic morphology.
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Volume 74, Number 2proximal location at which the graft fabric is apposed
360 to the aortic wall to the distal location at which
the graft fabric is apposed 360 to the aortic wall (for
our analysis, the recommended PAZ length was
$20 mm if the most proximal device were a FreeFlo
graft and $25 mm if the most proximal device were
a CoveredSeal graft, in accordance with the neck
lengths recommended in the instructions for use
[IFU])
d PAZ diameter: diameter at the proximal end of the
PAZ
d Distal oversizing: distal diameter of the most distal
stent graft divided by the aortic diameter immediately
distal to the aneurysm, minus one.
d Distal neck length: centerline distance from the distal
edge of the aneurysm to the proximal edge of the ce-
liac determined from the preprocedural imaging study
d Distal attachment zone (DAZ) length: centerline dis-
tance within the distal seal zone from the proximal
location at which graft fabric is apposed 360 to the
aortic wall to the distal location at which the graft fab-
ric is apposed 360 to the aortic wall (for our analysis,
the recommended DAZ length was $20 mm in accor-
dance with the IFU recommended distal neck length)
d DAZ diameter: diameter at the distal end of the DAZ
d Maximum thoracic aneurysm diameter: maximum
major axis of the thoracic aorta perpendicular to the
blood flow lumen
d Aneurysm length measured on postimplant images at
1 and 12 months: centerline distance from the distal
end of the PAZ to the proximal end of the DAZStatistical analysis. Continuous variables are presented
as the mean 6 standard deviation and categorical vari-
ables as proportions of patients. Categorical variables
were compared using the Fisher exact test. For contin-
uous variables, a t test was used to compare normally
distributed data and a Wilcoxon rank sum test for non-
normally distributed data. Estimates and P values were
calculated from a linear model for repeated measure-
ments. The time to major adverse events, all-cause
mortality, and aneurysm-related mortality were
analyzed using Kaplan-Meier survival analyses with the
Greenwood method used for the standard error esti-
mate. An interval censored survival analysis was used to
evaluate the interval to the development of endoleaks
The one year primary end point rate was calculated
based on the number of patients with events (m) and the
number of patients without events (k) following the for-
mula: primary end point rate ¼ m/(mþk). All statistical
analyses were performed using SAS, version 9.4 or later
(SAS Institute Inc, Cary, NC).
RESULTS
Clinical and imaging follow-up. Of the 100 patients
who had undergone implantation with the Valiant
Navion stent graft, 1 had died within the first 30 days,for 99 patients eligible for evaluation at 1 month. The 1-
month clinical and imaging compliance was 99% (98
of 99) and 98% (97 of 99), respectively. A total of 86
subjects were eligible for 1-year follow-up examination
(10 patients had died, 2 patients had withdrawn from the
study, and 1 patient was lost to follow-up). In addition, 1 of
the 86 patients had not yet completed their 1-year
follow-up visit at the time of the present analysis. The 1-
year compliance for the clinical and imaging examina-
tions both was 91% (78 of 86). Of the 99 patients eligible
for imaging studies at 1 month, 97 (98%) had undergone
computed tomography (CT) or magnetic resonance im-
aging. At the 1-year follow-up, 78 of the 86 eligible pa-
tients (91%) had undergone CT or magnetic resonance
imaging, although only 76 patient images had appro-
priate scan quality for the core laboratory assessment.
Baseline patient and anatomic characteristics and
procedural outcomes. The demographics and baseline
characteristics were similar to those previously reported
in the 30-day primary end point study13 (Supplementary
Table I, online only). Of the 100 patients, 24 (24%) had
hadanabdominal aortic aneurysmand 11 (11%)hadhadan
ascending thoracic aneurysm in addition to their thoracic
aortic aneurysm. The proportions of patients with a pri-
mary indication for TEVAR and the mean maximum
aneurysm diameter for the specific group as specified by
the core laboratory (Syntactx) imaging analysis were as
follows: fusiform aneurysm, 47% (mean aneurysm diam-
eter, 63.1 6 9.5 mm); saccular aneurysm, 28% (mean
diameter, 53.06 13.2mm); andPAU, 25% (meandiameter,
44.16 9.3 mm).
The core laboratory measurements of the preimplant
vessel diameters are also reported in Supplementary
Fig 2. Kaplan-Meier curves for freedom from all-cause
mortality, aneurysm-related mortality, and secondary
procedures through 1 year. 1Number of subjects at risk at
the beginning of the interval; survival estimates performed
at the end of the interval, with the standard error calcu-
lated using the Greenwood method.
Fig 1. Schematic of seal zone-relatedmeasurements. Note
that proximal and distal neck lengths were calculated
from preprocedural images and attachment zone lengths
and diameters were measured after the procedure (1 and
12 months in the present study). D2, Aortic diameter
immediately proximal to aneurysm; D4, aortic diameter
immediately distal to aneurysm for oversizing calculations;
Max, maximum.
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August 2021Table I (online only). Most patients had had only one device
implanted (55%), with 38 patients (38%) requiring two and
7 (7%) requiring three or more devices. Of the 100 patients,
73 had received a FreeFlo device (73%) as their proximal
graft, with the landing zone distributed as follows: zone
2, 28.8% (n ¼ 21); zone 3, 46.6% (n ¼ 34); and zone 4,
24.7% (n ¼ 18). The other 27 subjects had received a Cover-
edSeal device as their proximal graft, with the landing
zones distributed as follows: zone 2, 7.4% (n ¼ 2); zone 3,
40.7% (n ¼ 11); and zone 4, 51.9% (n ¼ 14).
The acute procedural outcomes were similar to those
reported in our primary end point report13
(Supplementary Table I, online only). No access or
deployment failures occurred during the index proced-
ure for any of the 100 subjects. Of the 23 subjects with
landing zone 2, 21 had complete coverage and 2 had par-
tial coverage of the left subclavian artery (LSA). The 2patients with partial LSA coverage did not undergo
revascularization, and 19 of the 21 patients with complete
LSA coverage had required a revascularization proced-
ure. Our review of the database showed that 13 of the re-
vascularizations were left carotid to left subclavian
bypass and 6 were left subclavian transpositions. Of the
19 revascularization procedures, 10 had been performed
adjunctively before stent graft implantation and 9
intraoperatively.
Clinical trial outcomes at 1 year. At 1 year, the primary
composite end point had been met (one-sided 95% up-
per confidence interval, 9.99%; P < .001), with only 4 of
eligible 89 patients (4.5%) experiencing access and/or
deployment failure and/or a major device effect. Through
the 1-year follow-up, the freedom from all-cause mor-
tality, aneurysm-related mortality, and secondary pro-
cedures was 89.8%, 97.0%, and 94.8%, respectively (Fig 2).
A review of the database revealed the cause of death for
the 10 patients who had died was aneurysm related for 4,
Table I. Major adverse events through 1 year (as reported
by site)
MAE 0-365 Days (n ¼ 100)a
Any 41 (41/100)
Cardiac disorder 24 (24/100)
Acute myocardial infarction 2 (2/100)
Unstable angina 1 (1/100)
Atrial fibrillation 8 (8/100)
Atrioventricular block 2 (2/100)
Congestive heart failure 10 (10/100)
Left ventricular failure 1 (1/100)
Tachycardia 1 (1/100)
Ventricular tachycardia 2 (2/100)
Nervous system disorder 9 (9/100)
Stroke 7 (7/100)
Paraplegia/spinal cord ischemia 2 (2/100)




Acute respiratory failure 1 (1/100)
Pulmonary embolism 2 (2/100)
Vascular disorder 7 (7/100)
Aortic dissection 2 (2/100)
Aortic rupture 1 (1/100)
MAE, Major adverse events.
Data presented as percentage (no./No.) of subjects who experienced
one or more MAE during the study period; a patient could have had
multiple MAE in different categories; thus, the number of patients in
each category might not be the sum of those in each subcategory;
each patient was counted only once in each category.
aNumber of subjects at risk at beginning of the interval.
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for 1, and pneumonia for 1 patient. Of the four aneurysm-
related mortalities, three had occurred on day 1 (retro-
grade type A dissection), day 24 (not related to the stent
graft but within the first 30 days), and day 35 (aortic arch
rupture) after implantation; the details have been re-
ported in the 30-day study.13 The fourth patient had un-
dergone an indium-111 white blood cell scan, which had
revealed findings consistent with stent graft infection on
day 268. The patient had failed to progress after treat-
ment for methicillin-resistant Staphylococcus aureus
sepsis and had died on day 280. Of the five patients who
had undergone a total of six secondary procedures, the
reason for the secondary procedure was retrograde type
A dissection, aortic arch rupture, type II endoleak,
infrarenal abdominal aortic aneurysm, type Ia endoleak,
and type Ib endoleak. Excluding the PAU subjects and
considering only the aneurysm patients in the present
trial did not change the survival curves for all-cause
mortality, aneurysm-related mortality, or secondary pro-
cedures (Supplementary Tables II and III; Supplementary
Fig, online only).The major adverse events are listed in Table I. Seven pa-
tients experienced strokes, of whom, four recovered
without sequelae and three with sequelae. The results
of the survival analyses of endoleaks through 1 year of
follow-up are listed in Table II. An additional two patients
had experienced a type Ib endoleak on days 379 and 423
after implant, which were within the 1-year follow-up
window and, thus, were included in the imaging analysis.
They were not included in the survival analyses owing to
the 1-year cutoff. Of the nine patients with an endoleak,
two had undergone a secondary procedure to correct
their endoleak. One patient with both type Ia and Ib
endoleaks was successfully treated with a Valiant Capti-
via stent graft (Medtronic) placed proximally and a fenes-
trated Cook device (Cook Medical, Bloomington, Ind)
placed distally. The second patient had a type II endo-
leak. After embolization of the LSA with a coil, follow-
up imaging confirmed the leak had resolved without
sequelae.
Aneurysm sac dynamics. Only 2 of the 76 patients with
images available for analysis (2.6%) had had an increase
in their maximum aneurysm diameter of $5 mm after
1 year. Of these two patients with a sac increase
$5 mm, one had had a type Ib endoleak (Fig 3) and
one had not developed any endoleak. Most of the pa-
tients had had stable sacs (81.6%; 62 of 76), and 12 (15.8%)
had had sac shrinkage of #5 mm at 1 year.
Aortic measurements related to seal zones. The results
of the imaging analysis of the proximal and distal seal
zones are presented in Table III. The mean device over-
sizing was 17% 6 12% at the proximal end. Although
three patients had not met the minimum required
proximal neck length according to the IFU, 36 of the 100
patients (36%) had had a short PAZ at 1 month using the
study definitions. The mean device oversizing at the
distal end was 20% 6 13%. All the patients had met the
minimum required distal neck length of 20 mm. How-
ever, again, the DAZ length was considered short for 31 of
the 100 patients (31%). Of the 25 patients with a PAU, 2
(8%) had had a proximal neck length that did not meet
the IFU requirements. In addition, the PAZ was consid-
ered short for 15 of these 25 patients (60%) using our
definition.
As stated previously, nine patients had developed
endoleaks, one of whom had also had a sac increase
>5 mm. An additional patient had had a sac increase
>5 mm but without an endoleak identified. The seal
zones for these 10 patients (for simplicity, the endoleak
group) were compared with the patients without an
endoleak or with a sac increase of <5 mm (no endoleak
group; Table III). With the understanding that this sub-
group analysis was limited by the low numbers, 5 of
the 10 patients (50%) in the endoleak group had had a
short PAZ compared with 31 of the 90 patients (34.4%)
Table II. Interval censored survival analysis of endoleaks
Endoleak
Interval censored estimate
0-30 Days 31-365 Days
All 96.0% 6 2.1% (100; 2; 15) 89.6% 6 3.2% (83; 5; 37)
Type I 98.9% 6 1.1% (100; 1; 15) 94.4% 6 2.4% (84; 2; 38)
Type Ia 98.9% 6 1.1% (100; 1; 15) 97.6% 6 1.6% (84; 1; 39)
Type Iba 100.0% 6 0.0% (100; 0; 15) 95.4% 6 2.2% (85; 2; 39)
Type II 98.0% 6 1.6% (100; 1; 15) 95.4% 6 2.1% (84; 3; 40)
Data presented as mean 6 standard deviation (no. at risk; no. of events; no. censored).
aTwo patients had had a type Ib endoleak on days 379 and 423 after implantation, which was within their 1-year follow-up window; however, these
were not included in the survival analyses because the interval censored method had a 365-day cutoff point.
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endoleak group, 4 (40%) had had proximal oversizing
of <10% compared with 29 of the 90 patients in the no
endoleak group (32.2%). At the distal end, six patients
in the endoleak group (60%) had had a short attach-
ment zone compared with 25 patients in the no endo-
leak group (27.8%). However, although two patients in
the endoleak group (20%) had had <10% oversizing, an
additional two patients had had borderline undersizing
at 10.3% and 10.7% oversizing. Every patient in the endo-
leak group had had at least one seal zone characteristic
that did not meet the recommendations.
Thoracic aorta morphometry: effect of graft on native
anatomy and vice versa. Changes in aortic morphology
are presented in Table IV. The tortuosity did not change
between the preprocedural and 1-month images.
Compared with 1-month images, the thoracic aorta
showed a significant increase in tortuosity at 1 year (from
1.46 to 1.49; P < .001). At 1 year, an average of 4.2 mm of
aortic elongation was found at the distal end of the graft
compared with 1.2 mm at the proximal end (Table IV).
Similarly, the aortic dilation was more pronounced at the
distal end of the graft, with an average increase of
2.8 mm at the DAZ compared with 1.6 mm at the PAZ at
1 year.
DISCUSSION
In the present 1-year analysis of the clinical trials, the pa-
tients treated with the Valiant Navion stent graft system
(Medtronic) exhibited positive outcomes. The overall sur-
vival of near 90% and freedom from aneurysm-related
mortalities >95% are in line with reports of other
contemporary devices.15-17 Sac shrinkage is an indication
of the successful exclusion of the aneurysm, and most
patients had had stable or decreasing sacs at 1 year,
similar to the results with other modern grafts.15,16 Similar
to other trials,16,17 the rates of endoleaks and secondary
procedures were also low in the present study. The low
mortality, endoleak, and secondary procedure rates sup-
port the use of TEVAR as a safe and effective treatment of
thoracic aneurysms.The investigation into the aortic morphology offers
several key insights for consideration in clinical practice.
Short necks are a risk factor for adverse events,18 and
we often found short seal zones in the patients who
had experienced endoleaks or a sac increase of
>5 mm. Although the differences in the endoleak and
no endoleak group comparisons were not statistically
significant, we believe the trends shown are still hypoth-
esis generating. We also quite a disparity in that almost
every patient met the IFU requirements for the neck
length but one third had had short proximal and/or
distal seal zone lengths. The difference in seal zone
length and available neck length was unlikely to have
resulted from an imprecise landing, because 100% of
the patients had had successful advancement and
deployment of the graft at the intended landing zone,
according to the previous report.13
Although we acknowledge the possibility of underre-
porting of suboptimal deployment, other factors could
have led to the “short” attachment zones. The definition
of a continuous 360 wall apposition is likely to be inter-
rupted by calcification19 or thrombus, which would lead
to a shorter seal zone length, although not necessarily
compromise the performance of the graft. In addition,
patients with PAU and isolated lesions might not warrant
excessive coverage.20,21 Thus, at the distal end, physicians
might opt for less coverage to mitigate the risk of spinal
cord ischemia.22,23 Despite these possible reasons for the
attachment zones measuring short, we place an
emphasis on achieving, at a minimum, the recommen-
ded seal zone length to minimize the risk of adverse
events.1,24 Physicians can improve the seal zone by
increasing the length of seal25 or improving apposition
of the graft to the artery wall.26
At 1 year, the trial cohort as a whole had experienced
dilation of the proximal and distal attachment zones.12
In most cases, the aortic diameter remained smaller
than the graft diameter, with no loss of seal as evi-
denced by the low type I endoleak rate. Although un-
dersized grafts are, intuitively, at risk of endoleaks,27
the radial forces imposed by excessive oversizing are a
Fig 3. Three-dimensional computed tomography (CT) reconstructions of two patients, both with sufficient neck
lengths according to instructions for use (IFU) recommendations. Top, A patient with a good proximal attachment
zone (PAZ) and close to 20 mm of distal attachment. After 1 year, the patient had no endoleaks and had positive
signs of sac regression. Bottom, A patient with a short PAZ and no distal seal (0-mm attachment zone length),
which resulted in a type Ib endoleak and an increase in both aneurysm sac diameter and length. Although
secondary procedures were successful in resolving the event, we believe this situation could have been avoided
with better preprocedural planning.
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Volume 74, Number 2risk factor for early dilation.28,29 The inclusion of patients
with PAU could also have biased the overall oversizing
numbers because the recommended oversizing for
PAU and other fragile tissues is generally <10%.30 With
an understanding that arterial dilation is naturally
occurring, adjunctive procedures to protect against
dilation could be considered as a part of the device
sizing algorithm.28,29
Most of the thoracic aorta lengthening in the present
cohort occurred distally.11,31 Stent grafts also have a ten-
dency to conform to the outer curvature of the aorta,
and the combination of aortic elongation and a shift to-
ward the outer curvature can lead to the distal coverage
being shorter than expected.32 Thus, it is important tohave a good distal seal zone to limit adverse events.5,33
Some available options to ensure a good distal seal
include using longer or multiple grafts, grafts with distal
fixation, or EndoAnchors (Medtronic) to improve distal
sealing and fixation.34 Patient follow-up and monitoring
of the seal zones, especially at the distal end, are also
recommended.
Finally, the significance of a conformable graft that
does not alter the native anatomy immediately after
implant should not be understated. Previous studies
have reported that stent graft implantation can
modify the aortic curvature and lead to increased
displacement forces,9,35 which is especially concern-
ing in fragile aorta scenarios.30,36 In the present study,
Table IV. Vessel tortuosity and aortic morphometry showing effect of stent graft implantation on tortuosity and occurrence
of aortic dilation and elongation after 1 year
Anatomic measurement Before implantation
After implantation
At 1 month At 12 months
Effect of graft implantation on native anatomy
Thoracic aorta tortuosity 1.45 6 0.02 1.46 6 0.02 1.49 6 0.02a
Abdominal aorta tortuosity 1.07 6 0.01 1.08 6 0.01 1.08 6 0.01
Effect of aortic remodeling on graft performance
LSA to celiac length 272.59 6 3.52 279.76 6 4.03a
LCC to proximal edge 57.37 6 4.88 58.60 6 4.84
Stent graft total covered 161.67 6 6.19 163.83 6 6.35
Distal edge to celiac artery 72.36 6 5.61 76.60 6 5.60a
Aneurysm length 92.22 6 6.22 82.78 6 6.49a
Maximum thoracic aneurysm diameter 57.21 6 1.33 55.41 6 1.41a
PAZ length 32.23 6 2.30 40.80 6 2.94a
PAZ diameter 30.43 6 0.51 31.98 6 0.54a
DAZ length 36.63 6 2.89 39.87 6 3.51
DAZ diameter 30.14 6 0.54 32.94 6 0.86a
DAZ, Distal attachment zone; LCC, left common carotid artery; LSA, left subclavian artery; PAZ, proximal attachment zone.
Data presented as mean 6 standard error, as estimated from the linear model.
aMeasurement was significantly different from that at earlier measurement (at P < .05 significance level); estimates and P values calculated from a
linear model for repeated measurements.




EL or sac increase $5 mm
(n ¼ 10)
No EL and sac increase <5 mm
(n ¼ 90) P value
Proximal seal zone
PNeck length, mma 62.07 6 44.20 60.72 6 35.10 62.22 6 45.25 .76
Short PNeck per IFUa 3.0 (3/100) 0.0 (0/10) 3.3 (3/90) 1.00
1-Month PAZ length, mm 32.25 6 22.59 25.21 6 17.87 33.09 6 23.03 .36
Short PAZ at 1 month 36.0 (36/100) 50.0 (5/10) 34.4 (31/90) .50
Proximal OS,a % 17 6 12 14 6 10 17 6 12 .42
Proximal OS <10%a 33.0 (33/100) 40.0 (4/10) 32.2 (29/90) .73
Distal seal zone
DNeck length,a mm 97.65 6 66.98 95.53 6 79.78 97.88 6 65.92 .73
Short DNeck per IFUa 0.0 (0/100) 0.0 (0/10) 0.0 (0/90) NA
1-Month DAZ length, mm 36.14 6 28.40 31.33 6 32.11 36.71 6 28.08 .30
Short DAZ at 1 month 31.0 (31/100) 60.0 (6/10) 27.8 (25/90) .08
Distal OS,a % 20 6 13 17 6 11 20 6 13 .62
Distal OS <10%a 23.0 (23/100) 20.0 (2/10) 23.3 (21/90) 1.00
DAZ, Distal attachment zone; DNeck, distal neck; EL, endoleak; IFU, instructions for use; OS, oversizing; PAZ, proximal attachment zone; PNeck,
proximal neck.
Data presented as mean 6 standard deviation or percentage (no./No.).
aNeck length and OS calculated from preprocedural imaging measurements.
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August 2021thoracic aorta tortuosity was not altered as a result of
stent graft implantation, showing that the device
conforms to the native anatomy. Despite the natural
increase in the tortuosity of the thoracic aorta after
1 year, the low rates of endoleaks and secondary pro-
cedures also suggest the seal zones were maintained
over time. Overall, the graft conformed to the arterialwall with good wall apposition, as have other modern
grafts.37
STUDY LIMITATIONS
Just as with any single-arm clinical trial, the cita-
tions of studies of other stent grafts were simply
to place our outcomes in context owing to the
Journal of Vascular Surgery Verzini et al 577
Volume 74, Number 2lack of a control group in the present trial. The
focus of the present analysis was on the imaging-
based parameters, and a slight decrease in the
use of CT as the imaging modality had occurred
at the 1-year follow-up. In addition, the sample
size of the trial was too small to power statistically
significant conclusions in the endoleak and PAU
subgroup comparisons. Finally, one-quarter of the
trial subjects had had PAUs, which is a different dis-
ease state than aneurysms. The differences in the
outcomes with the exclusion of those with PAUs
are presented in Supplementary Tables II and III
and the Supplementary Fig (online only).
CONCLUSIONS
In the present 1-year report of the clinical trial of the
Valiant Navion stent graft system (Medtronic), the pa-
tients had good outcomes, with mortality, endoleaks,
and secondary procedures all very low. The imaging anal-
ysis showed the role that the length of coverage and
oversizing play in achieving a good seal zone. Physicians
have a multitude of techniques to choose from to obtain
a good seal. Temporal changes in aortic morphology,
especially distal aortic elongation and arterial dilation,
should be considered during the TEVAR planning pro-
cess such that the graft will perform well in the long
term. Finally, further follow-up will be imperative
because morphologic changes are likely to be more sig-
nificant over time. Thus, follow-up in the present trial is
planned through 5 years.
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Supplementary Fig (online only). Survival analyses after
removal of patients with penetrating atherosclerotic ulcer
(PAU) because previous survival analyses might not have
been representative of a typical aneurysm cohort owing to
the inclusion of those with PAUs. The all-cause mortality
(ACM), aneurysm-related mortality (ARM), and secondary
procedure rates without those with PAU were similar to
those that had included the patients with PAUs.
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Supplementary Table I (online only). Patient de-
mographics, medical history, preimplant vessel diameters,
and acute procedural data
Characteristic
Full trial cohort (n ¼
100)
Female gender 40 (40/100)
Age, years 70.8 6 8.9
Cardiovascular
Carotid artery disease 18.6 (18/97)
Angina 9 (9/100)
Arrhythmia 27 (27/100)
Congestive heart failure 15 (15/100)
Coronary artery disease 33 (33/100)
Myocardial infarction 16 (16/100)
Abdominal aortic aneurysm 24 (24/100)
Ascending thoracic aneurysm 11 (11/100)
Peripheral vascular disease 14.1 (14/99)
Hypertension 87 (87/100)
Cerebrovascular/neurologic
Stroke/cerebral vascular accident 9 (9/100)





Tobacco use in previous 10 years 50.5 (50/99)
Chronic obstructive pulmonary disease 31.3 (31/99)
Renal insufficiency 22 (22/100)
Cancer 23 (23/100)






D1, aortic diameter 2 cm proximal to
aneurysm
29.1 6 3.6 (100/100)
D2, aortic diameter immediately
proximal to aneurysm
31.3 6 5.0 (100/100)
D3, maximum aneurysm diameter
Entire cohort 55.56 13.1 (100/100)
Patients with fusiform aneurysm
indication
63.1 6 9.5 (47/47)
Patients with saccular aneurysm
indication
53.0 6 13.2 (28/28)
Patients with PAU indication 44.1 6 9.3 (25/25)
D4, aortic diameter immediately
distal to aneurysm
30.2 6 5.4 (100/100)
D5, aortic diameter 2 cm distal to
aneurysm
28.9 6 4.7 (100/100)
D6, minimum left common iliac
diameter
9.7 6 2.5 (99/99)
(Continued)
Supplementary Table I (online only). Continued.
Characteristic
Full trial cohort (n ¼
100)
D7, minimum left external iliac diameter 7.6 6 1.9 (98/98)
D8, minimum left femoral diameter 7.8 6 1.7 (96/96)
D9, minimum right common iliac
diameter
9.8 6 2.4 (99/99)
D10, minimum right external iliac
diameter
7.5 6 1.8 (98/98)
D11, minimum right femoral diameter 7.7 6 1.6 (96/96)
Aortic diameter
At left subclavian artery 29.7 6 4.2 (100/100)
At 2 cm distal to left common
carotid artery
29.5 6 4.1 (100/100)
At 2.5 cm distal to left common
carotid artery
30.26 4.9 (100/100)
At 2.5 cm proximal to aneurysm 29.4 6 3.6 (100/100)
At 2 cm proximal to celiac artery 28.5 6 5.4 (100/100)
Maximum infrarenal aortic diameter 26.5 6 7.9 (100/100)
Acute procedural data












94.4 6 144.1 (98/
100)
Blood transfusion required 2 (2/100)
Volume of blood transfused, mL 600.0 6 0.0 (2/100)
Volume of contrast, mL 95.3 6 51.4 (99/100)
Total fluoroscopic time, minutes 12.1 6 9.0 (99/100)
Radiation exposure, mGy 506.0 (73/100; 31-
8502)
ICU stay after index procedure, hours 45.5 (70/100; 14-
584)
Hospital stay, days 7.5 6 7.0 (100/100)
ASA, American Society of Anesthesiologists; ICU, intensive care unit;
PAU, penetrating atherosclerotic ulcer.
Data presented as mean 6 standard deviation (no./No.), percentage
(no./No.), or median (no./No.; range).
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Supplementary Table III (online only). Reassessment of endoleak rates after removal of PAU cohort
Endoleak type
Interval censored estimate
0-30 Days 31-365 Days
All 96.6% 6 2.3% (75; 1; 13) 86.7% 6 4.1% (61; 5; 27)
Type I 98.6% 6 1.4% (75; 1; 13) 92.1% 6 3.3% (61; 2; 28)
Type Ia 98.6% 6 1.4% (75; 1; 13) 96.7% 6 2.1% (61; 1; 29)
IC, Interval censored; PAU, pensetrating atherosclerotic ulcer.
Data presented as mean 6 standard deviation (no. at risk; no. of events; no. censored).
Removal of PAU subjects did not overly change the survival estimates for those with endoleaks; of the 25 patients with PAU, only 1 had developed an
endoleak (type Ia); because no patient with PAU had developed a type Ib or II endoleak, those data were not included.
Supplementary Table II (online only). Seal zone measurements stratified by indicationa
Anatomic measurement
Indication
P valueAneurysm (n ¼ 75) PAU (n ¼ 25)
Proximal seal zone
PNeck length,b mm 62.85 6 45.16 59.72 6 41.96 .57
Short PNeck per IFUb 1.3 (1/75) 8.0 (2/25) .15
1-Month PAZ length, mms 34.20 6 22.12 26.23 6 23.46 .05
Short PAZ at 1 month 28.0 (21/75) 60.0 (15/25) .0032
Proximal OS,b % 17 6 12 18 6 10 .53
Proximal OS <10%b 34.7 (26/75) 28.0 (7/25) .63
Distal seal zone
DNeck length,b mm 93.32 6 64.15 110.63 6 74.70 .32
Short DNeck per IFUb 0.0 (0/75) 0.0 (0/25) NA
1-Month DAZ length, mm 35.79 6 27.98 37.21 6 30.27 .85
Short DAZ at 1 month 33.3 (25/75) 24.0 (6/25) .46
Distal OS,b % 19 6 13 22 6 13 .22
Distal OS <10%b 25.3 (19/75) 16.0 (4/25) .42s
DAZ, Distal attachment zone; DNeck, distal neck; IFU, instructions for use; NA, not applicable; OS, oversizing; PAU, penetrating atherosclerotic ulcer;
PAZ, proximal attachment zone; PNeck, proximal neck.
Data presented as mean 6 standard deviation or % (no./No.).
aAlthough patients with PAU were included in the clinical trial, they are likely to be treated differently in terms of the choice of oversizing and seal
zone length and could have had different changes in their aortic morphometry.
bNeck lengths and oversizing were calculated using the preprocedural imaging measurements.
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